Partnership Launches New Radiopharmaceutical Trial for TNBC
Cellectar Biosciences has selected Evestia Clinical as a full-service CRO for a Phase 1b study of CLR 125 in...
Leqembi Approved for Alzheimer’s Treatment in Australia
Australia’s Therapeutic Goods Administration has approved Leqembi (lecanemab) for adults with early Alzheimer’s disease who are APOE ε4 non-carriers...
Roche Presents New Ocrevus, Fenebrutinib Data at ECTRIMS
Roche used ECTRIMS 2025 to consolidate its multiple sclerosis franchise on two fronts: durability and diversification. New data show...
Synendos’ Positive Phase 1 Results Pave Way for Phase 2
Synendos Therapeutics has reported positive topline results from a completed Phase 1 program of SYT-510, a first-in-class selective endocannabinoid...
Biogen Announces Regulatory Update on High-Dose Nusinersen
Biogen has received a Complete Response Letter from the FDA for its supplemental filing to add a high‑dose regimen...
API & Mitacs Launch Pioneering Life Sciences Placement Program
Applied Pharmaceutical Innovation has launched the Life Sciences Placement Program in partnership with Mitacs, aiming to support 1,000 paid...
Synendos’ Phase 1 Breakthrough in Mental Health Treatment
Synendos Therapeutics reported positive topline Phase 1 results for SYT-510, a first-in-class Selective Endocannabinoid Reuptake Inhibitor, in healthy volunteers....
Veru’s Obesity Drug Breakthrough After Successful FDA Meeting
Veru has secured FDA feedback clearing a defined regulatory path for enobosarm, a selective androgen receptor modulator, as an...
IO Biotech to Present Promising New Melanoma Data at ESMO
IO Biotech will deliver a late-breaking oral presentation at ESMO 2025 with primary results from its randomized phase 3...
Mainz Biomed Announces New ColoAlert® Launch in Switzerland
Mainz Biomed has commercially launched ColoAlert, its non-invasive colorectal cancer screening test, in Switzerland following Swissmedic registration, a technology...